Youngman Oh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Youngman Oh has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
Elizabeth M. Wilson
From the Department of Pediatrics, School of Medicine, Oregon Health Sciences University, Portland, Oregon 97201
1 shared publicationRon G. Rosenfeld
From the Department of Pediatrics, School of Medicine, Oregon Health Sciences University, Portland, Oregon 97201
1 shared publicationYoshitaka Yamanaka
Department of Pediatrics, School of Medicine, Oregon Health Sciences University, Portland, Oregon 97201, USA
1 shared publication
Latest Publications
- 1 February 1998
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 47 (3) , 283-293
Igf-independent regulation of breast cancer growth by IGF binding proteins
The human IGFBP family consists of at least seven proteins, designated as IGFBP-1, -2, -3, -4, -5, -6, and-7. IGFBPs 1-6 bind IGF-I and IGF-II with high affinity whereas IGFBP-7, a newly identified...
- 1 February 1998
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 47 (3) , 283-293
Igf-independent regulation of breast cancer growth by IGF binding proteins
The human IGFBP family consists of at least seven proteins, designated as IGFBP-1, -2, -3, -4, -5, -6, and-7. IGFBPs 1-6 bind IGF-I and IGF-II with high affinity whereas IGFBP-7, a newly identified...
- Open Access
- 1 December 1997
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 272 (49) , 30729-30734
Inhibition of Insulin Receptor Activation by Insulin-like Growth Factor Binding Proteins
- 1 December 1997
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 272 (49) , 30729-30734
Open AccessInhibition of Insulin Receptor Activation by Insulin-like Growth Factor Binding Proteins
- 1 August 1997
- Published by Springer Nature in Endocrine
- Vol. 7 (1) , 111-113
IGFBPs and neoplastic models
The insulin-like growth factor binding proteins (IGFBPs) are a family of seven structurally homologous proteins that bind insulin-like growth factor 1 (IGF-1) and IGF-II with high affinity, thereby modulating the actions of IGFs. Several lines of recent evidence from various cell systems have suggested that IGFBPs, especially IGFBP-3, may play more active, IGF-independent, roles in growth regulation of cancer cells. In support of this hypothesis, the author has recently shown that IGFBP-3 binds specifically and with high affinity to the surface of various cell types and directly inhibits monolayer growth of these cells in an IGF-independent manner, presumably by specific interaction with cell membrane proteins that function as an IGFBP-3 receptor. The author’s current studies demonstrate that a new class of IGFBP, IGFBP-7, constitutes a low affinity member of the IGFBP family, but primarily functions as a modulator of cell growth in an IGF-independent manner, similar to the action observed with IGFBP-3 in breast cancer cells. The author’s studies on the mechanisms of action of the low affinity IGFBPs will provide insight into the IGF-independent actions of the classical high affinity IGFBPs and their impact on cancer cell growth.
- 1 August 1997
- Published by Springer Nature in Endocrine
- Vol. 7 (1) , 111-113
IGFBPs and neoplastic models
The insulin-like growth factor binding proteins (IGFBPs) are a family of seven structurally homologous proteins that bind insulin-like growth factor 1 (IGF-1) and IGF-II with high affinity, thereby modulating the actions of IGFs. Several lines of recent evidence from various cell systems have suggested that IGFBPs, especially IGFBP-3, may play more active, IGF-independent, roles in growth regulation of cancer cells. In support of this hypothesis, the author has recently shown that IGFBP-3 binds specifically and with high affinity to the surface of various cell types and directly inhibits monolayer growth of these cells in an IGF-independent manner, presumably by specific interaction with cell membrane proteins that function as an IGFBP-3 receptor. The author’s current studies demonstrate that a new class of IGFBP, IGFBP-7, constitutes a low affinity member of the IGFBP family, but primarily functions as a modulator of cell growth in an IGF-independent manner, similar to the action observed with IGFBP-3 in breast cancer cells. The author’s studies on the mechanisms of action of the low affinity IGFBPs will provide insight into the IGF-independent actions of the classical high affinity IGFBPs and their impact on cancer cell growth.